James P Fogarty
CIK 1224818 · President and CEO · last filed 2026-09-25
James P Fogarty is a President and CEO who has filed 34 SEC Form 4 insider transactions across 5 companies since 2009. The most recent filing, for DRI, was dated Sep 25, 2026. Across all open-market trades the lifetime net is +$1.1M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $6.1M across reported positions. 23 SEC filings were submitted jointly with DARDEN RESTAURANTS INC.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
DRI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
ORLANDO, FL 32819
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| DRI | Director | 27,434 | $216.35 | $5.94M | $639.5K | 24 | 2026-09-25 |
| Assertio Therapeutics, Inc (ASRT) Delisted | Director | 1,259 | $23.50 | $29.6K | $0 | 1 | 2019-05-09 |
| Assertio Therapeutics, Inc (DEPO) Delisted | Director | — | — | — | $0 | 3 | 2018-05-10 |
| RGS | Director | 1,294 | $29.00 | $37.5K | $0 | 4 | 2014-10-30 |
| CHRS | President and CEO | 125,000 | $0.99 | $123.8K | $468.6K | 2 | 2010-06-25 |
Recent Filings
34 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-25 | DRI | Grant (A) | — | $0 | EDGAR |
| 2026-09-18 | DRI | Exer (M) | +886 | $0 | EDGAR |
| 2025-09-19 | DRI | Mixed | +1,162 | $0 | EDGAR |
| 2024-09-20 | DRI | Mixed | +1,171 | $0 | EDGAR |
| 2024-01-03 | DRI | Exer (M) | +1,180 | $0 | EDGAR |
| 2023-09-22 | DRI | Mixed | +1,219 | $0 | EDGAR |
| 2023-07-05 | DRI | Exer (M) | +3,123 | $154.6K | EDGAR |
| 2022-09-23 | DRI | Mixed | +1,064 | $0 | EDGAR |
| 2021-09-24 | DRI | Grant (A) | — | $0 | EDGAR |
| 2020-09-24 | DRI | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.